Sagimet Biosciences Sets Q4 2026 Start for Phase 3 Acne Trial — Sagimet Biosciences Inc.

Event summary

Sagimet Biosciences plans to begin patient enrollment in its AURORA Phase 3 trial of denifanstat for moderate to severe acne in Q4 2026.
The trial will enroll approximately 800 U.S. patients, including 450 adolescents, across multiple clinical trial sites.
Denifanstat, an oral FASN inhibitor, aims to be the first innovative oral treatment for acne in over 40 years if approved.
The trial will use three co-primary endpoints assessed at week 12, followed by a 40-week open-label extension for long-term safety evaluation.

The big picture

Sagimet Biosciences is advancing its Phase 3 trial for denifanstat, targeting a significant unmet need in the acne treatment market. With no innovative oral treatments approved in over 40 years, denifanstat's success could reshape the landscape for moderate to severe acne management. The trial's outcomes will be critical in determining the drug's potential to capture a substantial share of the 10 million U.S. patients annually affected by moderate to severe acne.

What we're watching

Regulatory Pathway: Whether the Phase 3 trial results will support a successful NDA submission and expedite regulatory approval.
Market Differentiation: How denifanstat's novel mechanism of action will position it against existing acne treatments.
Execution Risk: The pace at which Sagimet can enroll and complete the trial, given the scale of the patient population.